Leping Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Leping Feng has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Ping Wang
Department of Nutrition and Health, Public Health School, Guilin Medical University, Guilin, Guangxi 541004, P.R. China
4 shared publicationsTingting Hu
Scientific Experiment Center, Biotechnology School, Guilin Medical University, Guilin, Guangxi 541004, P.R. China
4 shared publicationsYe Chen
Department of Nutrition and Health, Public Health School, Guilin Medical University, Guilin, Guangxi 541004, P.R. China
4 shared publicationsCongjie Cai
Department of Nutrition and Health, Public Health School, Guilin Medical University, Guilin, Guangxi 541004, P.R. China
3 shared publicationsLingyu Wang
Department of Nutrition and Health, Public Health School, Guilin Medical University, Guilin, Guangxi 541004, P.R. China
3 shared publicationsRiming Wei
Scientific Experiment Center, Biotechnology School, Guilin Medical University, Guilin, Guangxi 541004, P.R. China
3 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 32 (3) , 1
[Corrigendum] Endogenous Nampt upregulation is associated with diabetic nephropathy inflammatory‑fibrosis through the NF‑κB p65 and Sirt1 pathway; NMN alleviates diabetic nephropathy inflammatory‑fibrosis by inhibiting endogenous Nampt
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
- 8 July 2026
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 32 (3) , 1
Open Access[Corrigendum] Endogenous Nampt upregulation is associated with diabetic nephropathy inflammatory‑fibrosis through the NF‑κB p65 and Sirt1 pathway; NMN alleviates diabetic nephropathy inflammatory‑fibrosis by inhibiting endogenous Nampt
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
- Open Access
- 20 May 2026
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 32 (1) , 1
[Expression of Concern] Endogenous Nampt upregulation is associated with diabetic nephropathy inflammatory‑fibrosis through the NF‑κB p65 and Sirt1 pathway; NMN alleviates diabetic nephropathy inflammatory‑fibrosis by inhibiting endogenous Nampt
Following the publication of this paper, it was drawn to the Editor’s attention by a concerned reader that the Sirt1 western blotting data shown in Fig. 4A on p. 4187 were strikingly similar to the Sirtl western blotting data shown in Fig. 6A on p. 4188, even though the experimental conditions reported for these figure parts were apparently different. The authors have been contacted by the Editorial Office to offer an explanation for the apparent re‑use of the same data in this paper, and we are awaiting their response. Owing to the fact that the Editorial Office has been made aware of potential issues surrounding the scientific integrity of this paper, we are issuing an Expression of Concern to notify readers of this potential problem while the Editorial Office continues to investigate this matter further. [Experimental and Therapeutic Medicine 14: 4181‑4193, 2017; DOI: 10.3892/etm.2017.5098]
- 20 May 2026
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 32 (1) , 1
Open Access[Expression of Concern] Endogenous Nampt upregulation is associated with diabetic nephropathy inflammatory‑fibrosis through the NF‑κB p65 and Sirt1 pathway; NMN alleviates diabetic nephropathy inflammatory‑fibrosis by inhibiting endogenous Nampt
Following the publication of this paper, it was drawn to the Editor’s attention by a concerned reader that the Sirt1 western blotting data shown in Fig. 4A on p. 4187 were strikingly similar to the Sirtl western blotting data shown in Fig. 6A on p. 4188, even though the experimental conditions reported for these figure parts were apparently different. The authors have been contacted by the Editorial Office to offer an explanation for the apparent re‑use of the same data in this paper, and we are awaiting their response. Owing to the fact that the Editorial Office has been made aware of potential issues surrounding the scientific integrity of this paper, we are issuing an Expression of Concern to notify readers of this potential problem while the Editorial Office continues to investigate this matter further. [Experimental and Therapeutic Medicine 14: 4181‑4193, 2017; DOI: 10.3892/etm.2017.5098]
- Open Access
- 1 September 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (5) , 4181-4193
Endogenous Nampt upregulation is associated with diabetic nephropathy inflammatory‑fibrosis through the NF‑κB p65 and Sirt1 pathway; NMN alleviates diabetic nephropathy inflammatory‑fibrosis by inhibiting endogenous Nampt
Nicotinamide phosphoribosyltransferase (Nampt) is a key enzyme in the nicotinamide adenine dinucleotide (NAD+) biosynthetic pathway. Exogenous extra cellular Nampt has been reported to increase the synthesis of pro‑fibrotic molecules in various types of renal cells. However, the role of endogenous Namptenzymatic activity in diabetic renal cells, particularly those associated with inflammation and fibrosis through the nuclear factor (NF)‑κB p65 and sirtuin 1 (Sirt1) pathway is still unknown. In the present study, a possible mechanism by which endogenous Nampt upregulation affects the expression of pro‑inflammatory and pro‑fibrotic cytokines in vivo and in vitro, is reported. The present results demonstrate that the expression of vimentin and fibronectin was directly implicated in endogenous Nampt upregulation. The expression levels of Poly(ADP‑ribose) polymerase‑1, NF‑κB p65, forkhead box protein O1 and B‑cell lymphoma 2‑like protein 4 were also significantly increased at 96 h compared with control group (P<0.01) respectively in response to endogenous Nampt upregulation. Furthermore, the expression level of Sirt1 was significantly reduced (P<0.05), and the NAD and NADH levels, and the NAD/NADH ratio are significantly altered in STZ‑induced diabetic rats (P<0.01). Treatment with FK866 and nicotinamide mononucleotide (NMN) led to downregulation of vimentin and fibronectin, respectively. These results suggest a novel role of Nampt as a pro‑inflammatory cytokine of mesangial fibrotic signaling. The Nampt‑NF‑κB p65 and Sirt1 signaling pathway serves a pivotal role in affecting the expression of fibrosis factors in diabetic nephropathy (DN) glomerular fibrosis processing. It is also suggested that prevention of endogenous Nampt upregulation may be critical in the treatment of DN pro‑inflammatory fibrosis and NMN is likely to be a potential pharmacological agent for the treatment of resistant DN nephritic fibrosis.
- 1 September 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (5) , 4181-4193
Open AccessEndogenous Nampt upregulation is associated with diabetic nephropathy inflammatory‑fibrosis through the NF‑κB p65 and Sirt1 pathway; NMN alleviates diabetic nephropathy inflammatory‑fibrosis by inhibiting endogenous Nampt
Nicotinamide phosphoribosyltransferase (Nampt) is a key enzyme in the nicotinamide adenine dinucleotide (NAD+) biosynthetic pathway. Exogenous extra cellular Nampt has been reported to increase the synthesis of pro‑fibrotic molecules in various types of renal cells. However, the role of endogenous Namptenzymatic activity in diabetic renal cells, particularly those associated with inflammation and fibrosis through the nuclear factor (NF)‑κB p65 and sirtuin 1 (Sirt1) pathway is still unknown. In the present study, a possible mechanism by which endogenous Nampt upregulation affects the expression of pro‑inflammatory and pro‑fibrotic cytokines in vivo and in vitro, is reported. The present results demonstrate that the expression of vimentin and fibronectin was directly implicated in endogenous Nampt upregulation. The expression levels of Poly(ADP‑ribose) polymerase‑1, NF‑κB p65, forkhead box protein O1 and B‑cell lymphoma 2‑like protein 4 were also significantly increased at 96 h compared with control group (P<0.01) respectively in response to endogenous Nampt upregulation. Furthermore, the expression level of Sirt1 was significantly reduced (P<0.05), and the NAD and NADH levels, and the NAD/NADH ratio are significantly altered in STZ‑induced diabetic rats (P<0.01). Treatment with FK866 and nicotinamide mononucleotide (NMN) led to downregulation of vimentin and fibronectin, respectively. These results suggest a novel role of Nampt as a pro‑inflammatory cytokine of mesangial fibrotic signaling. The Nampt‑NF‑κB p65 and Sirt1 signaling pathway serves a pivotal role in affecting the expression of fibrosis factors in diabetic nephropathy (DN) glomerular fibrosis processing. It is also suggested that prevention of endogenous Nampt upregulation may be critical in the treatment of DN pro‑inflammatory fibrosis and NMN is likely to be a potential pharmacological agent for the treatment of resistant DN nephritic fibrosis.
- 26 June 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (2) , 1727-1731
Overexpressed eNOS upregulates SIRT1 expression and protects mouse pancreatic β cells from apoptosis
Loss of sirtuin 1 (SIRT1) activity may be associated with metabolic diseases, including diabetes. The aim of the present study was to investigate the potential effects of overexpressed endothelial nitric oxide synthase (eNOS) on cell proliferation and apoptosis with SIRT1 activation in the Min6 mouse pancreatic β cell line. A pcDNA3.0-eNOS plasmid was constructed and transfected into Min6 cells for 24 h prior to harvesting. eNOS expression was validated and SIRT1 expression was detected following plasmid transfection using reverse transcription-quantitative polymerase chain reaction and western blot analysis, which demonstrated that the expression levels of eNOS and SIRT1 were significantly upregulated. Furthermore, the cell proliferation and cell apoptosis of the Min6 cells were evaluated, using a cell counting kit-8 assay and flow cytometry, respectively. The results suggested that overexpressed eNOS promoted cell proliferation and inhibited cell apoptosis in Min6 cells. The interaction between eNOS and SIRT1 was explored through co-immunoprecipitation, and it found that there was a strong interaction between eNOS and SIRT1. In conclusion, overexpressed eNOS may induce SIRT1 activation, which is implied to play a protective role in Min6 cells, and eNOS may be a new therapeutic target for diseases such as type 2 diabetes.
- 26 June 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (2) , 1727-1731
Overexpressed eNOS upregulates SIRT1 expression and protects mouse pancreatic β cells from apoptosis
Loss of sirtuin 1 (SIRT1) activity may be associated with metabolic diseases, including diabetes. The aim of the present study was to investigate the potential effects of overexpressed endothelial nitric oxide synthase (eNOS) on cell proliferation and apoptosis with SIRT1 activation in the Min6 mouse pancreatic β cell line. A pcDNA3.0-eNOS plasmid was constructed and transfected into Min6 cells for 24 h prior to harvesting. eNOS expression was validated and SIRT1 expression was detected following plasmid transfection using reverse transcription-quantitative polymerase chain reaction and western blot analysis, which demonstrated that the expression levels of eNOS and SIRT1 were significantly upregulated. Furthermore, the cell proliferation and cell apoptosis of the Min6 cells were evaluated, using a cell counting kit-8 assay and flow cytometry, respectively. The results suggested that overexpressed eNOS promoted cell proliferation and inhibited cell apoptosis in Min6 cells. The interaction between eNOS and SIRT1 was explored through co-immunoprecipitation, and it found that there was a strong interaction between eNOS and SIRT1. In conclusion, overexpressed eNOS may induce SIRT1 activation, which is implied to play a protective role in Min6 cells, and eNOS may be a new therapeutic target for diseases such as type 2 diabetes.